Definition, diagnosis and management of dementia in Parkinson's disease: Recommendations of the Swiss Parkinson's Disease Dementia Study Group;Definition, diagnose und management der Parkinson-demenz: Empfehlungen der Swiss Parkinson's Disease Dementia Study Group

Schweizer Archiv fur Neurologie und Psychiatrie

Volumn 158, Issue 4, 2007, Pages 155-177

  Bassetti, Claudio L ^a   Fuhr, P ^b   Monsch, A ^b   Baronti, F ^c   Burkhard, P ^d   Conti, F ^e   Kaelin Lang, A ^f   Schnider, A ^g   Tettenborn, B ^h   Vingerhoets, F ⁱ   Waldvogel, D ^j  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c Bethesda Health Research   (United States)

^d Neurologische Klinik   (Switzerland)

^e Clinica Hildebrand   (Switzerland)

^f UNIVERSITY OF BERN   (Switzerland)

^g Rehabilitation   (Switzerland)

^h Neurologische Klinik   (Switzerland)

ⁱ LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^j Klinik St Anna   (Switzerland)

more..

Author keywords

Cholinesterase inhibitors; Cognitive disorders; Dementia; Dementia with diffuse Lewy bodies; Hallucinations; Parkinson's disease

Indexed keywords

AMANTADINE; ATROPINE; BENZODIAZEPINE; BIPERIDEN; DIGOXIN; DONEPEZIL; LEVODOPA; NEUROLEPTIC AGENT; PLACEBO; PREDNISONE; RIVASTIGMINE; SELEGILINE; SEROTONIN UPTAKE INHIBITOR; THEOPHYLLINE;

CLINICAL FEATURE; CLINICAL TRIAL; DEMENTIA; DEPRESSION; HALLUCINATION; HUMAN; PARKINSON DISEASE; QUALITY OF LIFE; REVIEW; SLEEP DISORDER;

EID: 34250315655     PISSN: 02587661     EISSN: None     Source Type: Journal    
DOI: 10.4414/sanp.2007.01844     Document Type: Review

References (49)

1. Hobson P, Meara J. The detection of dementia and cognitive impairment in a community population of elderly people with Parkinson's disease by use of the CAMCOG neuropsychological test. Age Ageing. 1999;28:39-43.
2. Aarsland D, Tandberg E, Larsen JP, Cummings JL. Frequency of dementia in Parkinson's disease. Arch Neurol. 1996;53:538-42.
3. Aarsland D, Andersen K, Larsen JP, Lolk A, Kragh-Sørensen P. Prevalence and characteristics of dementia in Parkinson's disease. Arch Neurol. 2003;60:387-92.
4. National Parkinson Foundation Web site: www.parkinson.org
5. Jellinger KA, Seppi K, Wenning GK, Poewe W. The impact of coexisting Alzheimer pathology on the natural history of Parkinson's disease. J Neural Transm. 2002;109(3):329-39.
6. Aarsland D, Andersen K, Larsen JP, Lolk A, Nielsen H, Kragh-Sørensen P. Risk of dementia in Parkinson's disease: a community-based, prospective study. Neurology. 2001;56:730-6.
7. Emre M. Dementia associated with Parkinson's disease. Lancet Neurol. 2003;2:229-37.
8. Galvin JE, Pollack J, Moriss JC. Clinical phenotype of Parkinson's disease dementia. Neurology. 2006;67:1605-11.
9. Hughes AJ, Ben-Shlomo Y, Daniel SE, Lees AJ. What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathologic study. Neurology. 2001;57:34-8.
10. Hughes AJ, Daniel SE, Ben-Shlomo Y, Lees AJ. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain. 2002;125:861-70.
11. Schnider A. Verhaltensneurologie. Eine Einführung für Ärzte und Psychologen. Stuttgart: Thieme; 2004.
12. Diagnostisches und statistisches Manual psychischer Störungen DSM IV. 4. Auflage. Göttingen: Hogrefe Verlag; 1996. (Original: American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th edition. Washington DC: American Psychiatric Association; 1994).
13. ICD-10: Basis ist die Website: Zentralinstitut für die kassenärztliche Versorgung in der Bundesrepublik Deutschland: www.zi-berlin.de/Zi_ICD10Browser/zi_icd_10_browser.htm.
14. Cummings JL, Benson DF. Dementia - a clinical approach. 2nd edition. Boston: Butterworth-Heinemann; 1992.
15. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 3rd, revised edition. Washington DC: American Psychiatric Association; 1987.
16. Burton EJ, McKeith IG, Burn DJ, Williams ED, O'Brien JT. Cerebral atrophy in Parkinson's disease with and without dementia: a comparison with Alzheimer's disease, dementia with Lewy bodies and controls. Brain. 2004;127:791-800.
17. McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien JT, Feldman H, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB consortium. Neurology. 2005;65:1863-72.
18. Nakano I, Hirano A. Parkinson's disease: neuron loss in the nucleus basalis without concomitant Alzheimer's disease. Ann Neurol. 1984;15:415-8.
19. Perry EK, Curtis M, Dick DJ, Candy JM, Atack JR, Bloxham CA, et al. Cholinergic correlates of cognitive impairment in Parkinson's disease: comparisons with Alzheimer's disease. J Neurol Neurosurg Psychiatry. 1985;48:413-21.
20. Perry RH, Perry EK, Smith CJ, Xuereb JH, Irving D, Whitford CA, et al. Cortical neuropathological and neurochemical substrates of Alzheimer's and Parkinson's diseases. J Neural Transm. 1987;24(Suppl):131-6.
21. Whitehouse PJ, Hedreen JC, White CL 3rd, Price DL. Basal forebrain neurons in the dementia of Parkinson's disease. Ann Neurol. 1983;13:243-8.
22. Kuhl DE, Minoshima S, Fessler JA, Frey KA, Foster NL, Ficaro EP, et al. In vivo mapping of cholinergic terminals in normal aging, Alzheimer's disease, and Parkinson's disease. Ann Neurol. 1996;40:399-410.
23. Ballard CG, Aarsland D, McKeith I, O'Brien J, Gray A, Cormack, et al. Fluctuations in attention. PD dementia vs DLB with parkinsonism. Neurology. 2002;59:1714-20.
24. Aarsland D, Cummings JL, Larsen JP. Neuropsychiatric differences between Parkinson's disease with dementia and Alzheimer's disease. Int J Geriatr Psychiatry. 2001;16:184-91.
25. Aarsland D, Ballard C, Larsen JP, McKeith I. A comparative study of psychiatric symptoms in dementia with Lewy bodies and Parkinson's disease with and without dementia. Int J Geriatr Psychiatry. 2001;16:528-36.
26. Folstein MF, Folstein SE, McHugh PR. "Mini Mental State" - a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189-98.
27. Levy G, Jacobs DM, Tang MX, Cote LJ, Louis ED, Alfaro B, et al. Memory and executive function impairment predict dementia in Parkinson's disease. Mov Disord. 2002;17(6):1221-6.
28. Beck AT, Hautzinger M, Bailer M, Worall H, Keller F. Beck-Depressions- lnventar. 2., überarbeitete Auflage. Göttingen: Hogrefe; 1995.
29. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatr. 1960;23:56-62.
30. Johns MW. Sleepiness in different situations measured by the Epworth Sleepiness Scale. Sleep. 1994;17(8):703-10.
31. Chaudhuri KR, Pal S, DiMarco A, Whately-Smith C, Bridgman K, Mathew R, et al. The Parkinson's disease sleep scale: a new instrument for assessing sleep and nocturnal disability in Parkinson's disease. J Neurol Neurosurg Psychiatry. 2002;73:629-35.
32. Hughes AJ, Daniel SE, Blankson S, Lees AJ. A clinicopathologic study of 100 cases of Parkinson's disease. Arch Neurol. 1993;50:140-8.
33. McKeith I, Mintzer J, Aarsland D, Burn D, Chiu H, Cohen-Mansfield J, et al. Dementia with Lewy bodies. Lancet Neurol. 2004;3:19-28.
34. Bergman J, Lerner V. Successful use of donepezil for the treatment of psychotic symptoms in patients with Parkinson's disease. Clin Neuropharmacol. 2002;25:107-10.
35. Aarsland D, Laake K, Larsen JP, Janvin C. Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study. J Neurol Neurosurg Psychiatry. 2002;72:708-12.
36. Leroi I, Brandt J, Reich SG, Lyketsos CG, Grill S, Thompson R, et al. Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson's disease. Int J Geriatr Psychiatry. 2004;19:1-8.
37. Ravina B, Putt M, Siderowf A, Farrar JT, Gillespie M, Crawley A, et al. Donepezil for dementia in Parkinson's disease: a randomised, double-blind, placebo-controlled, crossover study. J Neurol Neurosurg Psychiatry. 2005;76:934-9.
38. Reading PJ, Luce AK, McKeith IG. Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial. Mov Disord. 2001;16:1171-4.
39. Giladi N, Shabtai H, Gurevich T, Benbunan B, Anca M, Korczyn AD. Rivastigmine (Exelon) for dementia in patients with Parkinson's disease. Acta Neurol Scand. 2003;108:368-73.
40. Emre M, Aarsland D, Albanese A, Byrne EJ, Deuschl E, De Deyn PP, et al. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med. 2004;351:2509-18.
41. Shea C, MacKnight C, Rockwood K. Donepezil for treatment of dementia with Lewy bodies: a case series of nine patients. Int Psychogeriatr. 1998;10:229-38.
42. Fergusson E, Howard R. Donepezil for the treatment of psychosis in dementia with Lewy bodies. Int J Geriatr Psychiatry. 2000;15:280-1.
43. Samuel W, Caligiuri M, Galasko D, Lacro J, Marini M, McClure FS, et al. Better cognitive and psychopathologic response to donepezil in patients prospectively diagnosed as dementia with Lewy bodies: a preliminary study. Int J Geriatr Psychiatry. 2000;15:794-802.
44. Maidment I, Fox C, Boustani M. Cholinesterase inhibitors for Parkinson's disease dementia. Cochrane Database Syst Rev. 2006;(1):CD004747.
45. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry. 1984;141(11):1356-64.
46. Wild R, Pettit T, Burns A. Cholinesterase inhibitors for dementia with Lewy bodies. Cochrane Database Syst Rev. 2003;(3):CD003672.
47. McKeith I, Del Ser T, Spano P, Emre M, Wesnes K, Anand R, et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet. 2000;356:2031-6.
48. Miyasaki JM, Shannon K, Voon V, Ravina B, Kleiner-Fisman G, Anderson K, et al. Practice parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson's disease (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2006;66:996-1002.
49. Gagnon JF, Postuma RB, Montplaisir J. Update on the pharmacology of REM sleep behavior disorder. Neurology. 2006;67:742-7.